WO1992017173A2 - Utilisation de la riboflavine dans le traitement de maladies liees aux virus hiv, de l'herpes, de la retinite pigmentaire et du paludisme - Google Patents
Utilisation de la riboflavine dans le traitement de maladies liees aux virus hiv, de l'herpes, de la retinite pigmentaire et du paludisme Download PDFInfo
- Publication number
- WO1992017173A2 WO1992017173A2 PCT/FR1992/000296 FR9200296W WO9217173A2 WO 1992017173 A2 WO1992017173 A2 WO 1992017173A2 FR 9200296 W FR9200296 W FR 9200296W WO 9217173 A2 WO9217173 A2 WO 9217173A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- riboflavin
- vitamin
- herpes
- malaria
- preventive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to new therapeutic indications for vitamin B2 or riboflavin.
- This parenterally prescribed molecule for AIDS patients has been shown to have immediate, surprising and very favorable clinical effects. It was intended so far for other indications, in particular for the treatment of certain skin conditions.
- the main molecules currently in use or in the process of being used belong to four distinct therapeutic families.
- the first family comprises reverse transcriptase inhibitor drugs which are themselves subdivided into two categories consisting of nucleoside inhibitors and non-nucleoside inhibitors.
- nucleoside inhibitors three molecules are currently in use or being tested, these are AZT, DDI, DDC.
- AZT or zidovudine is the first and only remedy used so far on a large scale on sick HIV-positive subjects. Its indication has just been extended to non-sick HIV-positive subjects but this remedy is likely to lead to hematopoietic complications.
- DDT or dideoxy-inosine is being tested phase II and III. It would present a certain neurological and pancreatic toxicity.
- SDC or dideoxycytidine is under study. It is planned to use it as a third intention after AZT and DDI and possibly as a second invention after AZT.
- a new non-nucleoside molecule that inhibits reverse transcriptase is currently under study; it is BI-RG-587 which belongs to the family of dipyridodiazepinones.
- the second therapeutic family consists of protease inhibitors and more particularly the molecule U81749 active in vitro on HIV.
- the third therapeutic family consists of soluble CD4 or r.CD4, under study; it is the viral receptor at the level of the membrane of T4 lymphocytes. It would be used as a decoy for HIV.
- Dithiocarb or Imuthiol constitutes the fourth anti-HIV therapeutic family. It is under industrial development. It would have a major antioxidant, anti-radical action. In addition to the four types of remedy previously mentioned, it should be noted that certain molecules, such as quinolones and tetracyclines, have shown certain effects in vitro on the replication of HIV.
- Photosynthesis is universal; the AIDS virus is subjected to photosynthesis, it is activated by the ultraviolet.
- Herpes HSV1 and HSV2 viruses are activated by ultraviolet light: the recurrence of herpes infection linked to HSV1 during significant sunshine is well known. HSV2 with genital tropism also seems to respond to ultraviolet radiation. HSV2 irradiated with ultraviolet rays produces cancer in the hamster and transforms rat cells in vitro (A. Mammette, medical virology, p.45). As for the HIV viruses, if they are capable of being destroyed by different physical methods, they resist very well against ultraviolet irradiation.
- riboflavin also called vitamin B2
- vitamin B2 has an inhibitory activity against infection by HIV viruses and can be used in the treatment of diseases linked to these viruses.
- this molecule can also be used in the treatment of infections or diseases which may be related to excessive sunshine such as those due to herpes viruses. Finally, the applicant has shown the action of this molecule in the preventive and curative treatment of malaria and retinitis pigmentosa.
- the present invention therefore relates to the use of riboflavin for obtaining a medicament intended for the preventive and curative treatment of diseases linked to HIV viruses and in particular for the treatment of AIDS.
- Another object of the present invention is the use of this molecule for obtaining medicaments intended for the preventive and curative treatment of herpes, retinitis pigmentosa and / or malaria.
- these molecules can be used for obtaining medicaments intended for the preventive and curative treatment of diseases related to light.
- Some examples of photoprotection with products or substances pigmented in yellow are well known: thus beta-carotenes by stimulating skin pigmentation protect the skin against UV rays and patients suffering from pigmentary retinitis wear yellow-orange glasses to slow down scalability of the disease. Their colored vision is then reduced by its blue color. It is remarkable to note that riboflavin exists in a physiological state in an appreciable quantity in the retina. We can assume that in the event of a vitamin B2 deficiency, the retina which is no longer protected by this photoprotective molecule would undergo aggression by ultraviolet rays and the free radicals they generate, this aggression causing or aggravating damage to the level of visual cells.
- vitamin PP or AZT are associated with riboflavin.
- riboflavin and vitamin PP are in synergistic amounts.
- Warburg riboflavin or yellow ferment plays an essential role in the cellular respiratory chain where it acts in symbiosis with vitamin PP itself known for certain photoprotective effects since it is prescribed in lucites.
- vitamins PP are carriers of hydrogen; this transfer action between hydrogen and oxygen at the cellular and mitochondrial membranes suggests without the applicant being bound by this hypothesis an anti-radical effect, that is to say antioxidant, of vitamins B2 and PP .
- the medicaments according to the invention are advantageously for oral or parenteral use.
- the substances pigmented in yellow and orange-yellow absorb ultraviolet and blue radiation.
- the riboflavin molecule is yellow-orange in color in crystallized form. In solution, it gives a yellow-green fluorescence; his exposure, even for a few minutes, to ultra- violet causes its irreversible decomposition into its antagonistic derivative lumiflavin which gives a blue fluorescence in solution.
- the drugs are preferably placed in opaque light and ultraviolet conditioning.
- Riboflavin has properties capable of confirming its inhibitory action on the replication of HIV.
- riboflavin goes through two active metabolites, FMN and FAD or flavin-mononucleotide and flavin-adenine-dinucleotide. It should be noted that certain dinucleoside molecules such as AZT, DDI, DDC are inhibitors of HIV reverse transcriptase.
- EXAMPLE 1 Therapeutic use of riboflavin associated with AZT.
- a 30-year-old patient with stage IV AIDS is put on RETROVIR anti-tuberculosis treatment (AZT) with 6 capsules per day.
- RIBOFLAVINE Treatment with RIBOFLAVINE as an adjuvant to the previous one is started about a month later.
- the multiplication of HIV1 (BRU strain) in CEM or CEM-SS cells is evaluated, after 5 days of infection, by a reverse transcriptase (RT) assay, the activity of which translates the presence of virus released into the supernatant of culture.
- RT reverse transcriptase
- Riboflavin anti-HIV1 activity has been shown for a dilution to approximately 1/5000 of a 10 mg / ml solution of riboflavin (Beflavin sold by the company ROCHE). For higher concentrations, a toxicity of the preparation has been observed which is supposed to be due to one or more of the excipients of the commercial preparation. The effect of riboflavin has also been tested on a patient with herpes.
- vitamin B2 by its colorimetric, biological and physiological properties, is a treatment of choice for AIDS infection, all the more so since, without this hypothesis committing the applicant, there could be a deficiency of this vitamin by excess of sunshine and / or by imbalance in the food ration with excess of lipids and carbohydrates at the expense of the protein ration; this nutritional imbalance, common in underdeveloped countries, causes excessive elimination of vitamin B2 in the urine.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4508599A JPH06506212A (ja) | 1991-04-02 | 1992-04-02 | Hivウイルス系疾病、ヘルペス、色素性網膜炎およびマラリアの治療向けリボフラビンの利用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR91/04218 | 1991-04-02 | ||
FR9104218A FR2674753B1 (fr) | 1991-04-02 | 1991-04-02 | Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1992017173A2 true WO1992017173A2 (fr) | 1992-10-15 |
WO1992017173A3 WO1992017173A3 (fr) | 1993-01-07 |
Family
ID=9411559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1992/000296 WO1992017173A2 (fr) | 1991-04-02 | 1992-04-02 | Utilisation de la riboflavine dans le traitement de maladies liees aux virus hiv, de l'herpes, de la retinite pigmentaire et du paludisme |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0578733A1 (fr) |
JP (1) | JPH06506212A (fr) |
AU (1) | AU1654092A (fr) |
CA (1) | CA2107078A1 (fr) |
FR (1) | FR2674753B1 (fr) |
OA (1) | OA09819A (fr) |
WO (1) | WO1992017173A2 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2696319A1 (fr) * | 1992-10-02 | 1994-04-08 | Berque Jean | Utilisation de produits biologiques atoxiques et principalement de la riboflavine dans la fabrication des préservatifs et des gants de protection médico-chirurgicaux. |
EP0643775A1 (fr) * | 1992-05-28 | 1995-03-22 | Monash University | Compositions therapeutiques |
WO1995011028A1 (fr) * | 1993-10-19 | 1995-04-27 | Radopath Limited | Derives de flavine utilises comme agents antiviraux |
US5730971A (en) * | 1993-12-27 | 1998-03-24 | Sanwa Kagaku Kenkyusho Co., Ltd. | Potentiator for interferon and an antiviral activity-potentiating composition containing interferon and its potentiator |
GB2319474A (en) * | 1993-10-19 | 1998-05-27 | Radopath Ltd | Anti-viral agents |
WO2002074313A1 (fr) * | 2001-03-21 | 2002-09-26 | Eisai Co., Ltd. | Médicaments à base de vitamine b2 réduite |
US9044523B2 (en) | 2000-06-15 | 2015-06-02 | Terumo Bct, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ244270A (en) * | 1991-09-13 | 1995-07-26 | Eisai Co Ltd | Injectable composition comprising riboflavin |
US6258577B1 (en) | 1998-07-21 | 2001-07-10 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers |
US6277337B1 (en) | 1998-07-21 | 2001-08-21 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using photosensitizers |
US6268120B1 (en) | 1999-10-19 | 2001-07-31 | Gambro, Inc. | Isoalloxazine derivatives to neutralize biological contaminants |
US7985588B2 (en) | 2000-06-02 | 2011-07-26 | Caridianbct Biotechnologies, Llc | Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light |
TW590780B (en) | 2000-06-02 | 2004-06-11 | Gambro Inc | Additive solutions containing riboflavin |
US7648699B2 (en) | 2000-06-02 | 2010-01-19 | Caridianbct Biotechnologies, Llc | Preventing transfusion related complications in a recipient of a blood transfusion |
US6548241B1 (en) | 2000-11-28 | 2003-04-15 | Gambro, Inc. | Storage solution containing photosensitizer for inactivation of biological contaminants |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2096712A1 (en) * | 1970-06-29 | 1972-02-25 | Giraux Georges | Steroid/b group vitamin compsns - for prevention and treatment of skin-photosensitivity disorders |
GB1431841A (en) * | 1973-01-15 | 1976-04-14 | Evans S C | Ophthalmic-nutritional preparations |
JPS59172417A (ja) * | 1983-03-23 | 1984-09-29 | Nisshin Kagaku Kk | リボフラビン酪酸エステル含有軟カプセル |
EP0196515A1 (fr) * | 1985-03-14 | 1986-10-08 | Baxter Travenol Laboratories, Inc. | Inactivation photodynamique de virus dans des compositions thérapeutiques contenant des protéines |
DE3542309A1 (de) * | 1985-11-29 | 1987-06-04 | Cardona Federico Dr | Medizinisches antioxidativum |
WO1991004744A1 (fr) * | 1989-10-06 | 1991-04-18 | The Beth Israel Hospital Association | Procede et appareil de traitement d'etats pathologiques a l'aide de lipoproteines oxydees |
WO1991007168A1 (fr) * | 1989-11-09 | 1991-05-30 | Schering-Plough Healthcare Products, Inc. | Riboflavine comme promoteur du tannage |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2559569A1 (de) * | 1975-10-22 | 1977-04-28 | Josef Hofmann | Fluessiges futtermittel fuer brieftauben |
US4500524A (en) * | 1982-09-15 | 1985-02-19 | Trustees Of Boston University | Tranquilizing and reducing or preventing seizures |
-
1991
- 1991-04-02 FR FR9104218A patent/FR2674753B1/fr not_active Expired - Fee Related
-
1992
- 1992-04-02 CA CA002107078A patent/CA2107078A1/fr not_active Abandoned
- 1992-04-02 AU AU16540/92A patent/AU1654092A/en not_active Abandoned
- 1992-04-02 WO PCT/FR1992/000296 patent/WO1992017173A2/fr not_active Application Discontinuation
- 1992-04-02 EP EP92909405A patent/EP0578733A1/fr not_active Withdrawn
- 1992-04-02 JP JP4508599A patent/JPH06506212A/ja active Pending
-
1993
- 1993-10-01 OA OA60422A patent/OA09819A/fr unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2096712A1 (en) * | 1970-06-29 | 1972-02-25 | Giraux Georges | Steroid/b group vitamin compsns - for prevention and treatment of skin-photosensitivity disorders |
GB1431841A (en) * | 1973-01-15 | 1976-04-14 | Evans S C | Ophthalmic-nutritional preparations |
JPS59172417A (ja) * | 1983-03-23 | 1984-09-29 | Nisshin Kagaku Kk | リボフラビン酪酸エステル含有軟カプセル |
EP0196515A1 (fr) * | 1985-03-14 | 1986-10-08 | Baxter Travenol Laboratories, Inc. | Inactivation photodynamique de virus dans des compositions thérapeutiques contenant des protéines |
DE3542309A1 (de) * | 1985-11-29 | 1987-06-04 | Cardona Federico Dr | Medizinisches antioxidativum |
WO1991004744A1 (fr) * | 1989-10-06 | 1991-04-18 | The Beth Israel Hospital Association | Procede et appareil de traitement d'etats pathologiques a l'aide de lipoproteines oxydees |
WO1991007168A1 (fr) * | 1989-11-09 | 1991-05-30 | Schering-Plough Healthcare Products, Inc. | Riboflavine comme promoteur du tannage |
Non-Patent Citations (19)
Title |
---|
Annali di Ottalmologia e Clinica Oculistica, vol. 94, no. 8, août 1968, R. CUPPINI et al.: "Terapia lattoflavinica della cheratite erpetica", pages 926-928, voir le document en entier * |
Annals of the New York Academy of Sciences, vol. 587, 1990, J.D. BOGDEN et al.: "Micronutrient status and human immunodeficiency virus (HIV) infection", pages 189-195, voir le document en entier * |
Japanese Journal of Ophthalmology, vol. 21, no. 3, 1977, Y. TANO et al.: "Photodynamic inactivation of herpes simplex virus", pages 392-398, voir le document en entier, surtout tableau 1 * |
Korea Univ. Med. J., vol. 16, no. 1, 1979, J.P. KIM: "A study on the effect of hibon (riboflavin tetrabutyrate) on arteriosclerotic retinopathy, diabetic retinopathy and cataract", pages 299-306, voir le document en entier * |
Osaka Kyoiku Daigaku Kiyo, Dai-3-Bumon, vol. 28, nos. 2-3, 1980, S. FUJISHITA et al.: "Identification of flavin derivatives contained in the frog retina and pigment layer", pages 135-139, voir le document en entier * |
Osaka Kyoiku Daigaku Kiyo, vol. 35, no. 1, août 1986, S. FUJISHITA et al.: "The quantitative relation between the riboflavin in the choroid and the rhodopsin in the retina", pages 123-128, voir le document en entier * |
Patent Abstracts of Japan, vol. 9, no. 21 (C-263), 29 janvier 1985, & JP,A,59172417 (NITSUSHIN KAGAKU K.K.) 29 septembre 1984, voir résumé en entier * |
Photochemistry and Photobiology, vol. 24, no. 3, septembre 1976, Pergamon Press, (GB), O.M. PEREIRA et al.: "Photosensitization of human diploid cell cultures by intracellular flavins and protection by antioxidants", pages 237-242, voir le document en e ntier * |
R. BERKOW et al.: "The Merck Manual of Diagnosis and Therapy", 15 édition, 1987, Merck & Co., Inc., Rahway, NJ, US, voir page 2234: "Retinitis pigmentosa" * |
The American Journal of Clinical Nutrition, vol. 51, no. 5, mai 1990, American Society for Clinical Nutrition, B.S. DAS et al.: "Increased plasma lipid peroxidation in riboflavin-deficient malaria-infected children1-3", pages 859-863, voir le document en entier * |
The American Journal of Tropical Medicine and Hygiene, vol. 37, no. 3, novembre 1987, The American Society of Tropical Medicine and Hygiene, W.B. COWDEN et al.: "Antimalarial activity of a riboflavin analog against Plasmodium vinckei in vivo and Plasmodium falciparum in vitro", pages 495-500, voir le document en entier * |
The FASEB Journal, vol. 3, no. 3, 9 février 1989, E. MANTERO-ATIENZA et al.: "Nutritional status of a cohort of HIV-1 positive gay men", voir page A657, résumé no. 2502, voir résumé en entier * |
The Journal of Investigative Dermatology, vol. 58, no. 4, avril 1972, (US), D. ROTH et al.: "Protective action of flavins on ultraviolet irradiated DNA", pages 233-237, voir le document en entier * |
The Journal of Investigative Dermatology, vol. 65, no. 6, décembre 1975, L.J. PACERNICK et al.: "The inefficacy of riboflavin against ultraviolet-induced carcinogenesis", pages 547-548, voir le document en entier * |
The Journal of Nutrition, vol. 117, no. 1, janvier 1987, C.D. ECKHERT: "Differential effects of riboflavin and RRR-alpha-tocopheryl acetate on the survival of newborn RCS rats with inheritable retinal degeneration", pages 208-211, voir le document en entier * |
The Journal of Protozoology, vol. 32, no. 1, février 1985, The Society of Protozoologists, T.G. GEARY et al.: "Nutritional requirements of Plasmodium falciparum in culture. II. Effects of antimetabolites in a semi-defined medium", pages 65-69, voir le document en entier * |
The Lancet, vol. 2, no. 8463, 9 novembre 1985, P. DUTTA et al.: "Antimalarial effects of riboflavin deficiency", pages 1040-1043, voir le document en entier * |
Vestn. Oftal. (USSR), vol. 3, 1974, G.A. VINKOVA: "Riboflavin and ascorbic acid in a diseased healthy cornea", pages 39-40, voir résumé anglais * |
Vestn. Oftamol., vol. 6, novembre-décembre 1978, L.A. KATSNELSON et al.: "Experience of treating with the drug fad (elavin-adeninenucleotide) of central tapeto-retinal abiotrophies", pages 63-67, voir le document en entier * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0643775A4 (fr) * | 1992-05-28 | 1995-12-27 | Univ Monash | Compositions therapeutiques. |
EP0643775A1 (fr) * | 1992-05-28 | 1995-03-22 | Monash University | Compositions therapeutiques |
US5981601A (en) * | 1992-05-28 | 1999-11-09 | Centre For Molecular Biology And Medicine | Method for enhancing cellular bioenergy |
WO1994007499A1 (fr) * | 1992-10-02 | 1994-04-14 | Jean Berque | Utilisation de derives de la flavine pour la realisation d'articles d'hygiene medico-chirurgicaux et les articles d'hygiene ainsi realises |
FR2696319A1 (fr) * | 1992-10-02 | 1994-04-08 | Berque Jean | Utilisation de produits biologiques atoxiques et principalement de la riboflavine dans la fabrication des préservatifs et des gants de protection médico-chirurgicaux. |
WO1995011028A1 (fr) * | 1993-10-19 | 1995-04-27 | Radopath Limited | Derives de flavine utilises comme agents antiviraux |
AP620A (en) * | 1993-10-19 | 1997-10-14 | Radopath Ltd | Uses of a flavin in the treatment of ill-effects caused by viral infections. |
GB2319474A (en) * | 1993-10-19 | 1998-05-27 | Radopath Ltd | Anti-viral agents |
GB2283913A (en) * | 1993-10-19 | 1995-05-24 | Radopath Ltd | Anti-viral agents comprising flavins |
US5730971A (en) * | 1993-12-27 | 1998-03-24 | Sanwa Kagaku Kenkyusho Co., Ltd. | Potentiator for interferon and an antiviral activity-potentiating composition containing interferon and its potentiator |
US9044523B2 (en) | 2000-06-15 | 2015-06-02 | Terumo Bct, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
WO2002074313A1 (fr) * | 2001-03-21 | 2002-09-26 | Eisai Co., Ltd. | Médicaments à base de vitamine b2 réduite |
US7579325B2 (en) | 2001-03-21 | 2009-08-25 | Eisai R & D Management Co., Ltd. | Drugs containing reduced of vitamin B2 |
Also Published As
Publication number | Publication date |
---|---|
CA2107078A1 (fr) | 1992-10-03 |
FR2674753A1 (fr) | 1992-10-09 |
OA09819A (fr) | 1994-04-15 |
JPH06506212A (ja) | 1994-07-14 |
AU1654092A (en) | 1992-11-02 |
WO1992017173A3 (fr) | 1993-01-07 |
FR2674753B1 (fr) | 1995-03-10 |
EP0578733A1 (fr) | 1994-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cravotto et al. | Phytotherapeutics: an evaluation of the potential of 1000 plants | |
US5945106A (en) | Montoxic extract of Larrea tridentata and method of making the same | |
WO1992017173A2 (fr) | Utilisation de la riboflavine dans le traitement de maladies liees aux virus hiv, de l'herpes, de la retinite pigmentaire et du paludisme | |
US7270838B2 (en) | Composition for treating chronic venous insufficiencies using an extract of red vine leaves | |
EP0732927B1 (fr) | Compositions d'entre autres la riboflavine pour la protection locale des muqueuses genitales et rectales | |
FR2633182A1 (fr) | Composition pharmaceutique anticancereuse et methode d'utilisation de l'invention | |
US8557310B2 (en) | Composition to retard the onset of symptoms of alzheimer's disease | |
FR2715303A1 (fr) | Utilisation du FAD et/ou du NAD comme médicaments. | |
EP0225831B1 (fr) | Utilisation d'huiles hyperoxygénées pour la fabrication d'un médicament pour le traitement de l'herpès. | |
CZ290794A3 (en) | Antemetic composition | |
EP2274000B1 (fr) | Composition pharmaceutique ou dietetique comprenant des extraits aqueux de nigella sativa et d'olea europea et/ou phyllantus amarus | |
EP0722325B1 (fr) | Composition pour le traitement ou la prevention de l'herpes | |
EP0402208B1 (fr) | Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique | |
JP2003159028A (ja) | 花粉症治療用食品 | |
EP0502765B1 (fr) | Nouvelles compositions diététiques à base de lipides complexes phosphorés et leur utilisation dans les troubles du sommeil | |
US7358278B2 (en) | Cellular phosphorylation potential enhancing compositions preparation and use thereof | |
WO1994007499A1 (fr) | Utilisation de derives de la flavine pour la realisation d'articles d'hygiene medico-chirurgicaux et les articles d'hygiene ainsi realises | |
US20090156649A1 (en) | Cellular phosphorylation potential enhancing compositions preparation and use thereof | |
FR3111541A1 (fr) | Extrait d'un champignon de la famille des BOLETUS FUNGI pour son utilisation notamment dans la prévention de la maladie Covid 19 | |
CA2181885A1 (fr) | Solution injectable de fluorure de benzalkonium | |
WO2021099453A1 (fr) | Extrait liquide aqueux de spiruline pour la prévention et/ou le traitement des neuropathies périphériques chimio-induites et leurs symptômes, composition et utilisation correspondantes | |
RU2182823C1 (ru) | Способ лечения больных псориазом в сочетании с хроническим описторхозом | |
KR930011995B1 (ko) | 백내장 치료용 조성물 | |
WO1995028945A1 (fr) | Compositions antivirales pour le traitement du sida et procede de preparation | |
WO1999017609A1 (fr) | Extrait non toxique de larrea tridentata et son procede de production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BR CA CS FI HU JP NO PL RO RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |
Free format text: PL |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU BR CA CS FI HU JP NO PL RO RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992909405 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2107078 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1992909405 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1994 129051 Country of ref document: US Date of ref document: 19940210 Kind code of ref document: A |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992909405 Country of ref document: EP |